1 AIMS AND OBJECTIVES/BACKGROUND: Nursing is a predominant
2 AIMS dyskinesia score was also reduced in the 40 mg/day
3 AIMS is a nurse-led, 1-on-1 self-management intervention
4 AIMS OF THE STUDY: To compare sociodemographic, clinical
5 AIMS was delivered by nurses during routine clinic visit
6 AIMS/HYPOTHESIS: We have previously shown the implicatio
7 AIMS: Doxorubicin (DOX), a widely used anticancer agent,
8 AIMS: The recent and ongoing worldwide expansion in prev
9 AIMS: This two phase study aimed to explore health care
10 AIMS: To (i) estimate the diagnostic accuracy of ThermoS
11 AIMS: To assess in a pilot study whether (i) Allergy Dia
12 AIMS: To compare the risk of vascular disease, HbA1c and
13 AIMS: To determine the incidence of functional stroke mi
14 AIMS: To identify neural network differences in the hemo
15 AIMS: To quantify the volume, type and costs, in a Unite
16 Additionally,
AIMS was cost-effective (ie, dominant: cheaper and more
17 BACKGROUND
AND AIMS: Diabetes mellitus is likely to have a major effect
18 BACKGROUND
AND AIMS: Duodenoscopes have been implicated in the transmis
19 BACKGROUND
AND AIMS: Hyperoxaluria after Roux-en-Y gastric bypass (RYGB
20 BACKGROUND
AND AIMS: Immunosuppressive therapy for inflammatory bowel d
21 BACKGROUND
AND AIMS: Proteomics holds promise for individualizing cance
22 BACKGROUND
AND AIMS: The IL28B genotype has been linked to sustained vi
23 BACKGROUND
AND AIMS: The mammalian intestinal epithelium self-renews ra
24 BACKGROUND
AND AIMS: The risk of hepatocellular cancer (HCC) after sust
25 BACKGROUND
AND AIMS: Tumor necrosis factor (TNF) is a cytokine that pro
26 BACKGROUND &
AIMS: 5-hydroxytryptamine receptor (5-HT(4)R) agonists p
27 BACKGROUND &
AIMS: A diagnosis of celiac disease is made based on cli
28 BACKGROUND &
AIMS: A reduction in portal pressure gradient (PPG) to <
29 BACKGROUND &
AIMS: A system is needed to determine the risk of patien
30 BACKGROUND &
AIMS: A variety of fecal immunochemical tests (FITs) for
31 BACKGROUND &
AIMS: Accurate optical analysis of colorectal polyps (op
32 BACKGROUND &
AIMS: Activating mutations in KRAS are detected in most
33 BACKGROUND &
AIMS: Administration of tryptophan and some of its metab
34 BACKGROUND &
AIMS: Adult stem cells have been proposed to be quiescen
35 BACKGROUND &
AIMS: After careful pilot studies and planning, the nati
36 BACKGROUND &
AIMS: Agents that induce an immune response against tumo
37 BACKGROUND &
AIMS: Alagille syndrome is a genetic disorder characteri
38 BACKGROUND &
AIMS: Algorithms for diagnosis of malignant common bile
39 BACKGROUND &
AIMS: Alterations in signaling pathways that regulate re
40 BACKGROUND &
AIMS: Although interleukin 28B (interferon, lambda 3) (I
41 BACKGROUND &
AIMS: Although the adenoma detection rate is used as a m
42 BACKGROUND &
AIMS: Although there is a genetic predisposition to colo
43 BACKGROUND &
AIMS: Although tumor necrosis factor (TNF) antagonists r
44 BACKGROUND &
AIMS: Although we are beginning to understand where, whe
45 BACKGROUND &
AIMS: Among patients with large colorectal sessile polyp
46 BACKGROUND &
AIMS: Among subjects screened for colorectal cancer (CRC
47 BACKGROUND &
AIMS: Approximately 10% of children on the liver transpl
48 BACKGROUND &
AIMS: Approximately 50% of all patients with pancreatic
49 BACKGROUND &
AIMS: Ascites are the most common complication of cirrho
50 BACKGROUND &
AIMS: Autosomal recessive polycystic kidney disease (ARP
51 BACKGROUND &
AIMS: Basiliximab is a chimeric monoclonal antibody that
52 BACKGROUND &
AIMS: Cardiovascular disease (CVD) is the leading cause
53 BACKGROUND &
AIMS: CD4+ T-regulatory (Treg) cells suppress immune res
54 BACKGROUND &
AIMS: Celiac disease is a chronic small intestinal infla
55 BACKGROUND &
AIMS: Celiac disease is characterized by HLA-DQ2/8-restr
56 BACKGROUND &
AIMS: Cell stress signaling pathways result in phosphory
57 BACKGROUND &
AIMS: Cell therapy offers the potential to treat gastroi
58 BACKGROUND &
AIMS: Central neuromodulators (antidepressants, antipsyc
59 BACKGROUND &
AIMS: Central obesity promotes gastroesophageal reflux,
60 BACKGROUND &
AIMS: Certain subsets of colorectal serrated polyps (SP)
61 BACKGROUND &
AIMS: Cholangiocarcinomas (CCA) are resistant to chemoth
62 BACKGROUND &
AIMS: Cholecystectomy (CCY) after an episode of choledoc
63 BACKGROUND &
AIMS: Cholera toxin can act as a modulator of the immune
64 BACKGROUND &
AIMS: Chronic hepatitis affects phenotypes of innate and
65 BACKGROUND &
AIMS: Chronic hepatitis C virus (HCV) infection is a maj
66 BACKGROUND &
AIMS: Chronic, excessive alcohol consumption leads to al
67 BACKGROUND &
AIMS: Clinical studies showed teduglutide to increase ur
68 BACKGROUND &
AIMS: Colorectal cancer (CRC) screening using quantitati
69 BACKGROUND &
AIMS: Concurrent to development of more effective drugs
70 BACKGROUND &
AIMS: Consumption of sugar is associated with obesity, t
71 BACKGROUND &
AIMS: Cytokinesis can fail during normal postnatal liver
72 BACKGROUND &
AIMS: Daclatasvir is a direct-acting antiviral agent and
73 BACKGROUND &
AIMS: De novo synthesis of guanosine diphosphate (GDP)-f
74 BACKGROUND &
AIMS: Depletion of interstitial cells of Cajal (ICCs) is
75 BACKGROUND &
AIMS: Despite inducing an inflammatory response, Helicob
76 BACKGROUND &
AIMS: Diagnosis of inflammatory bowel diseases (IBD) is
77 BACKGROUND &
AIMS: Diarrhea associated with inflammatory bowel diseas
78 BACKGROUND &
AIMS: Dietary fiber is implicated as a risk factor for d
79 BACKGROUND &
AIMS: Dietary restriction of fermentable carbohydrates (
80 BACKGROUND &
AIMS: Direct oral anticoagulant (DOAC) agents increase t
81 BACKGROUND &
AIMS: Drugs that inhibit the erb-b2 receptor tyrosine ki
82 BACKGROUND &
AIMS: Dysbiosis of the intestinal microbiota has been as
83 BACKGROUND &
AIMS: Effective treatments are needed for hepatic steato
84 BACKGROUND &
AIMS: Elbasvir (an NS5A inhibitor) and grazoprevir (an N
85 BACKGROUND &
AIMS: Endoscopic ultrasound (EUS)-guided chemoablation w
86 BACKGROUND &
AIMS: Endoscopists do not routinely follow guidelines to
87 BACKGROUND &
AIMS: Endoscopy is an integral part of the investigation
88 BACKGROUND &
AIMS: Epigenetic mechanisms might be involved in the reg
89 BACKGROUND &
AIMS: Estrogen has been proposed to modulate gut inflamm
90 BACKGROUND &
AIMS: Excellent single-center outcomes of neoadjuvant ch
91 BACKGROUND &
AIMS: Fecal microbiota transplantation (FMT) is a highly
92 BACKGROUND &
AIMS: Feeding during the first months of life might affe
93 BACKGROUND &
AIMS: Few studies have examined the association between
94 BACKGROUND &
AIMS: Fibrolamellar hepatocellular carcinoma (FL-HCC) is
95 BACKGROUND &
AIMS: Foodborne illness affects 15% of the US population
96 BACKGROUND &
AIMS: For 4 decades, stigmata of recent hemorrhage in pa
97 BACKGROUND &
AIMS: For patients with Barrett's esophagus, the diagnos
98 BACKGROUND &
AIMS: Functional constipation (FC) is a common childhood
99 BACKGROUND &
AIMS: Gastric hypersensitivity (GHS) contributes to epig
100 BACKGROUND &
AIMS: Gastrointestinal (GI) diseases account for substan
101 BACKGROUND &
AIMS: Gastroparesis is a complication of diabetes with f
102 BACKGROUND &
AIMS: GATA3 is a transcription factor that regulates T-c
103 BACKGROUND &
AIMS: Gluten ingestion leads to symptoms and small intes
104 BACKGROUND &
AIMS: Healthy eating patterns assessed by diet quality i
105 BACKGROUND &
AIMS: Helicobacter pylori is remarkable for its genetic
106 BACKGROUND &
AIMS: Hepatic encephalopathy (HE) is a serious complicat
107 BACKGROUND &
AIMS: Hepatitis B virus (HBV) infects hepatocytes, but t
108 BACKGROUND &
AIMS: Hepatitis E virus (HEV) infection is a major cause
109 BACKGROUND &
AIMS: Hepatocellular adenomas (HCAs) are benign liver tu
110 BACKGROUND &
AIMS: Hirschsprung disease is caused by failure of enter
111 BACKGROUND &
AIMS: Human tumors and liver cancer cell lines express t
112 BACKGROUND &
AIMS: Immunodeficiency and autoimmune sequelae, includin
113 BACKGROUND &
AIMS: Improved therapy has substantially increased survi
114 BACKGROUND &
AIMS: In colorectal tumors, hypoxia causes resistance to
115 BACKGROUND &
AIMS: In most patients with Parkinson's disease, gastroi
116 BACKGROUND &
AIMS: Individuals with cystic fibrosis are at increased
117 BACKGROUND &
AIMS: Individuals with cystic fibrosis are at increased
118 BACKGROUND &
AIMS: Inefficient fatty acid oxidation in mitochondria a
119 BACKGROUND &
AIMS: Infections are common in patients with severe alco
120 BACKGROUND &
AIMS: Inflammatory bowel diseases (IBD) increase risk fo
121 BACKGROUND &
AIMS: Inflammatory bowel diseases (IBDs) increase the ri
122 BACKGROUND &
AIMS: Inhibitors of the epidermal growth factor receptor
123 BACKGROUND &
AIMS: Inhibitors of the hepatitis C virus (HCV) NS5A pro
124 BACKGROUND &
AIMS: Interactions between commensal microbes and the im
125 BACKGROUND &
AIMS: Interferon-free direct-acting antiviral (DAA) ther
126 BACKGROUND &
AIMS: Intestinal epithelial homeostasis is maintained by
127 BACKGROUND &
AIMS: Intraductal papillary mucinous neoplasias (IPMNs)
128 BACKGROUND &
AIMS: Invariant natural killer T (iNKT) cells undergo ca
129 BACKGROUND &
AIMS: Irritable bowel syndrome (IBS) is associated with
130 BACKGROUND &
AIMS: It is a challenge to deliver nucleic acids to gast
131 BACKGROUND &
AIMS: It is not clear how the complex interactions betwe
132 BACKGROUND &
AIMS: It might be possible to manipulate the intestinal
133 BACKGROUND &
AIMS: Knowledge of temporal associations between screen-
134 BACKGROUND &
AIMS: Ligand binding to inhibitory receptors on immune c
135 BACKGROUND &
AIMS: Little is known about factors associated with a su
136 BACKGROUND &
AIMS: Little is known about factors that regulate intest
137 BACKGROUND &
AIMS: Little is known about provider and health system f
138 BACKGROUND &
AIMS: Little is known about substitutions that mediate r
139 BACKGROUND &
AIMS: Little is known about the absolute risk of hepatoc
140 BACKGROUND &
AIMS: Little is known about the causes of heartburn in p
141 BACKGROUND &
AIMS: Little is known about the development of branch du
142 BACKGROUND &
AIMS: Little is known about the incidence of celiac dise
143 BACKGROUND &
AIMS: Little is known about the prevalence and burden of
144 BACKGROUND &
AIMS: Little is known about the signaling pathways that
145 BACKGROUND &
AIMS: Liver cirrhosis is complicated by bleeding from po
146 BACKGROUND &
AIMS: Liver regeneration after partial hepatectomy (PH)
147 BACKGROUND &
AIMS: Low activity of natural killer (NK) cells has been
148 BACKGROUND &
AIMS: Low estrogen levels can contribute to development
149 BACKGROUND &
AIMS: Macrophages mediate the epithelial response to Hel
150 BACKGROUND &
AIMS: Magnetic resonance imaging (MRI) techniques and ul
151 BACKGROUND &
AIMS: Maintenance and differentiation of progenitor cell
152 BACKGROUND &
AIMS: Many different types of cancer cells have chromoso
153 BACKGROUND &
AIMS: Many patients with a < 1 cm segment of columnar me
154 BACKGROUND &
AIMS: Many patients with inflammatory bowel diseases (IB
155 BACKGROUND &
AIMS: MEDI2070 is a human monoclonal antibody that selec
156 BACKGROUND &
AIMS: Microparticles released into the bloodstream upon
157 BACKGROUND &
AIMS: MicroRNAs (miRNAs) can promote or inhibit tumor gr
158 BACKGROUND &
AIMS: MicroRNAs (miRNAs) have been implicated in the dev
159 BACKGROUND &
AIMS: Multiple endoscopic bariatric therapies (EBTs) cur
160 BACKGROUND &
AIMS: Narrow-band imaging is an image-enhanced form of e
161 BACKGROUND &
AIMS: Neural stem and progenitor cells from the enteric
162 BACKGROUND &
AIMS: New-onset diabetes in patients with pancreatic can
163 BACKGROUND &
AIMS: Non-celiac gluten sensitivity is characterized by
164 BACKGROUND &
AIMS: Nonalcoholic fatty liver disease (NAFLD) is a cons
165 BACKGROUND &
AIMS: Nonalcoholic fatty liver disease (NAFLD) is associ
166 BACKGROUND &
AIMS: Nosocomial infections with Clostridium difficile p
167 BACKGROUND &
AIMS: Obesity-related insulin resistance contributes to
168 BACKGROUND &
AIMS: Paneth cell dysfunction causes deficiencies in int
169 BACKGROUND &
AIMS: Patients with acute liver failure (ALF) have defec
170 BACKGROUND &
AIMS: Patients with acute liver failure (ALF) have high
171 BACKGROUND &
AIMS: Patients with celiac disease should maintain a glu
172 BACKGROUND &
AIMS: Patients with chronic hepatitis C virus (HCV) geno
173 BACKGROUND &
AIMS: Patients with chronic hepatitis C virus (HCV) infe
174 BACKGROUND &
AIMS: Patients with hepatitis C virus-associated cirrhos
175 BACKGROUND &
AIMS: Patients with inflammatory liver disease commonly
176 BACKGROUND &
AIMS: Patients with severe alcoholic hepatitis (AH) have
177 BACKGROUND &
AIMS: People infected with human immunodeficiency virus
178 BACKGROUND &
AIMS: Pharmacologic treatment of eosinophilic esophagiti
179 BACKGROUND &
AIMS: Polymorphisms in the IL28B gene have been associat
180 BACKGROUND &
AIMS: Polymorphisms that reduce the function of nucleoti
181 BACKGROUND &
AIMS: Poorly digested, fermentable carbohydrates may ind
182 BACKGROUND &
AIMS: Preclinical studies have shown aspirin to have ant
183 BACKGROUND &
AIMS: Previous studies have suggested that dietary folic
184 BACKGROUND &
AIMS: Previous studies reported that black vs white disp
185 BACKGROUND &
AIMS: Primary sclerosing cholangitis (PSC) is an orphan
186 BACKGROUND &
AIMS: Probiotics can reduce symptoms of irritable bowel
187 BACKGROUND &
AIMS: Progression of liver fibrosis in experimental mode
188 BACKGROUND &
AIMS: Prostaglandin-endoperoxide synthase (Ptgs)2 is an
189 BACKGROUND &
AIMS: Proton pump inhibitors (PPI) are among the top 10
190 BACKGROUND &
AIMS: Proton pump inhibitors (PPI) have been associated
191 BACKGROUND &
AIMS: Proton pump inhibitors (PPIs) and histamine-2 rece
192 BACKGROUND &
AIMS: Proton pump inhibitors (PPIs) are commonly used me
193 BACKGROUND &
AIMS: Recommendations for surveillance after curative su
194 BACKGROUND &
AIMS: Relative risk of colorectal cancer (CRC) decreases
195 BACKGROUND &
AIMS: Resistance of metastatic human colorectal cancer c
196 BACKGROUND &
AIMS: Roux-en-Y gastric bypass (RYGB) improves glucose h
197 BACKGROUND &
AIMS: Separation of newborn rats from their mothers indu
198 BACKGROUND &
AIMS: Signaling lymphocyte activation molecule (Slamf)1
199 BACKGROUND &
AIMS: Smoking, an independent risk factor for pancreatit
200 BACKGROUND &
AIMS: Statin use has been associated with a reduced inci
201 BACKGROUND &
AIMS: Studies have reported associations between proton
202 BACKGROUND &
AIMS: Studies of Clostridium difficile infections (CDIs)
203 BACKGROUND &
AIMS: Studies of the pressure response of the upper esop
204 BACKGROUND &
AIMS: Surveillance guidelines for serrated polyps (SPs)
205 BACKGROUND &
AIMS: Surveillance of patients with cirrhosis increases
206 BACKGROUND &
AIMS: Survival times vary among patients with neuroendoc
207 BACKGROUND &
AIMS: Systematic reviews have provided evidence for the
208 BACKGROUND &
AIMS: Tests to measure serum endomysial antibodies (EMA)
209 BACKGROUND &
AIMS: The association between prevalence of celiac disea
210 BACKGROUND &
AIMS: The canonical Wnt signaling pathway activates the
211 BACKGROUND &
AIMS: The clinical course of chronic pancreatitis is unp
212 BACKGROUND &
AIMS: The efficacy of abatacept, a selective costimulati
213 BACKGROUND &
AIMS: The enteric nervous system (ENS) regulates gastroi
214 BACKGROUND &
AIMS: The goal of treatment for Barrett's esophagus (BE)
215 BACKGROUND &
AIMS: The guidelines of the European Society of Pediatri
216 BACKGROUND &
AIMS: The gut microbiota affects host lipid and glucose
217 BACKGROUND &
AIMS: The IMAgINE 1 study (NCT00409682) evaluated the sa
218 BACKGROUND &
AIMS: The incidence and mortality of hepatocellular carc
219 BACKGROUND &
AIMS: The incidence of colorectal cancer (CRC) in indivi
220 BACKGROUND &
AIMS: The increase in use of anesthesia assistance (AA)
221 BACKGROUND &
AIMS: The inflammatory bowel diseases (IBD) ulcerative c
222 BACKGROUND &
AIMS: The innate immune system responds not only to bact
223 BACKGROUND &
AIMS: The mitochondrial nicotinamide adenine dinucleotid
224 BACKGROUND &
AIMS: The multiple endocrine neoplasia, type 1 (MEN1) lo
225 BACKGROUND &
AIMS: The nuclear receptor subfamily 1 group H member 4
226 BACKGROUND &
AIMS: The pathogenesis of cirrhosis, a disabling outcome
227 BACKGROUND &
AIMS: The pathogenesis of liver fibrosis involves activa
228 BACKGROUND &
AIMS: The purpose of this review is to evaluate the risk
229 BACKGROUND &
AIMS: The quality of endoscopists' colonoscopy performan
230 BACKGROUND &
AIMS: The role of sphincter of Oddi manometry (SOM) in t
231 BACKGROUND &
AIMS: The role of the intestine in the maintenance of ch
232 BACKGROUND &
AIMS: The role of tobacco smoke in the etiology of infla
233 BACKGROUND &
AIMS: The signaling molecule and transcriptional regulat
234 BACKGROUND &
AIMS: The type III interferons (IFN-lambdas: interleukin
235 BACKGROUND &
AIMS: Therapies for perianal fistulas in patients with C
236 BACKGROUND &
AIMS: There are few effective treatments for nausea and
237 BACKGROUND &
AIMS: There is controversy over the ability of transjugu
238 BACKGROUND &
AIMS: There is controversy regarding the role of the typ
239 BACKGROUND &
AIMS: There is growing interest in the use of bone marro
240 BACKGROUND &
AIMS: There is suboptimal inter-observer agreement, even
241 BACKGROUND &
AIMS: Tumor necrosis factor (TNF) is an inflammatory cyt
242 BACKGROUND &
AIMS: Use of aspirin and/or non-aspirin nonsteroidal ant
243 BACKGROUND &
AIMS: Use of monitored anesthesia care (MAC) for gastroi
244 BACKGROUND &
AIMS: Variants in the tumor necrosis factor superfamily
245 BACKGROUND &
AIMS: Video capsule endoscopy (CE) provides a noninvasiv
246 BACKGROUND &
AIMS: Visceral hypersensitivity is one feature of irrita
247 BACKGROUND &
AIMS: We analyzed DNA methylation patterns and transcrip
248 BACKGROUND &
AIMS: We assessed the diagnostic performance of magnetic
249 BACKGROUND &
AIMS: We developed comprehensive models to determine ris
250 BACKGROUND &
AIMS: We have limited knowledge about the association be
251 BACKGROUND &
AIMS: We investigated the roles of interleukin 28A (also
252 BACKGROUND &
AIMS: We investigated whether patients with multiple ser
253 BACKGROUND &
AIMS: We performed a prospective study to investigate th
254 BACKGROUND &
AIMS: Western and prudent dietary patterns have been ass
255 BACKGROUND &
AIMS: Wheat amylase-trypsin inhibitors (ATIs) are nutrit
256 BACKGROUND &
AIMS: When the glial fibrillary acidic protein (GFAP) pr
257 BACKGROUND &
AIMS: Wilson disease is a disorder of copper (Cu) misbal
258 BACKGROUND &
AIMS: Zinc homeostasis in cells is maintained through ti
259 BACKGROUND, &
AIMS: Studies of primary biliary cirrhosis (PBC) phenoty
260 BACKGROUND/
AIMS: Chronic kidney disease (CKD) is an important comor
261 BACKGROUND/
AIMS: Depression is associated with an increased risk fo
262 BACKGROUND/
AIMS: Patients with vestibular disease have been observe
263 BACKGROUND/
AIMS: The ability to extract depth from disparity may be
264 fied intention-to-treat population (
baseline AIMS score >/=6 and at least one post-baseline rating).
265 (items 1-7), as assessed by blinded
central AIMS video raters.
266 ndomly assigned participants (1:1) to
either AIMS or treatment as usual (ie, containing a range of co
267 uares mean change from baseline to week 6
in AIMS dyskinesia score was -3.2 for the 80 mg/day group,
268 The mean (SE) change
in AIMS score was -4.9 (0.4) at Week 54 (n = 146), - 6.3 (0
269 baseline to week 12, the least-squares
mean AIMS score improved by -3.3 points (SE 0.42) in the deut
270 es suggests that over a period of 15
months,
AIMS may be costlier, but also more effective than TAU.
271 Implementation
of AIMS in routine clinical HIV care is therefore recommend
272 Moreover, the improvement
of AIMS total score correlated with the increase in BDNF le
273 ning sessions of 6 h each (18 h in total)
on AIMS and a 1.5 h booster training session at the clinic
274 re randomized to treatment as usual (TAU)
or AIMS in a multicenter randomized controlled trial in the
275 breast cancer signature outperformed
PAM50,
AIMS, SCMGENE and IntClust subtyping predictors.
276 From a healthcare
perspective,
AIMS dominated TAU.
277 From a societal
perspective,
AIMS was slightly more expensive than TAU but also more
278 In terms of
QALYs,
AIMS resulted in higher costs but more QALYs compared to
279 Motor function [Alberta Infants Motor
Scale (
AIMS)] and clinical symptoms (parental questionnaire) we
280 on the Abnormal Involuntary Movement
Scale (
AIMS) dyskinesia score (items 1-7), as assessed by blind
281 ange in Abnormal Involuntary Movement
Scale (
AIMS) score (items 1 to 7) from baseline and the proport
282 ange in Abnormal Involuntary Movement
Scale (
AIMS) score from baseline to week 12 in patients with at
283 idated by Accurate Inclusion Mass
Screening (
AIMS) and immunostaining and supported for the retinal g
284 Here, we use ab initio multiple
spawning (
AIMS) with spin-restricted ensemble Kohn-Sham (REKS) the
285 dherence Improving self-Management
Strategy (
AIMS) compared with treatment as usual.
286 dherence Improving Self-Management
Strategy (
AIMS), from a societal perspective, with a 15-month time
287 In this
study,
AIMS reduced viral load, increased QALYs, and saved reso
288 d Intellectual disability Myopathy
Syndrome (
AIMS).
289 luation with a lifetime horizon showing
that AIMS is cost-effective.
290 ngs from preparatory studies have shown
that AIMS is acceptable, feasible to deliver in routine care,
291 All additional analyses suggest
that AIMS is cheaper and more effective than TAU.
292 f the base case analyses also suggested
that AIMS dominates TAU.
293 The AIMS trial is registered with the ISRCTN registry, numbe
294 opies per mL [95% CI 35.5-55.9]) than in
the AIMS group (estimated marginal mean 35.4 copies per mL [
295 Furthermore, improvement in
the AIMS score was greatest in those with the Val/Val allele
296 The median (IQR) increase in
the AIMS score was higher in the cobalamin group than in the
297 3412) or placebo (1707 [50%] of 3412) in
the AIMS trial.
298 using data from 3412 women recruited to
the AIMS trial, a randomised, double-blind, placebo-controll
299 mple comprised 221 patients; 109 assigned
to AIMS and 112 to treatment as usual.
300 nt Instrument for Mental Health Systems (
WHO-
AIMS) were included in multiple regression analyses to i